Perspective Therapeutics Inc (CATX) - News Archive

Perspective Therapeutics Inc., a company specializing in innovative radiopharmaceuticals for cancer treatment, has recently shared updated interim data from its ongoing Phase 1/2a clinical trial of ^212PbVMT-NET at the...

New Appointment Signals Strategic Growth for Perspective Therapeutics In a significant move for the advancement of its corporate governance and strategic vision, Perspective Therapeutics, Inc. has announced the appointm...

In recent months, the intersection of cutting-edge research and clinical development in the fight against cancer has taken a significant leap forward, as evidenced by the latest updates from Perspective Therapeutics (NY...

Perspective Therapeutics Innovative Radiopharmaceutical Data Accepted for Presentation at 2025 ASCO Annual MeetingApril 23, 2025 SEATTLE Perspective Therapeutics, a leading radiopharmaceutical company dedicated to pione...

Perspective Therapeutics Financial Outlook and Market Performance: A Closer LookAs Perspective Therapeutics Inc. prepares to release its first quarter 2025 financial results, market observers are keenly dissecting its r...

In a significant milestone for Perspective Therapeutics Inc. (CATX), the company recently announced that the first patient has been dosed with 212PbVMT01 as a monotherapy in the Phase 1/2a study targeting MC1R-positive...

Radiopharmaceutical Pioneer Perspective Therapeutics to Unveil 2024 Financial Results Amidst Market Rebound Shifts The Seattle-based radiopharmaceutical trailblazer, Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX),...

As the leaves turn and the year approaches its close, the world of healthcare investment is brimming with opportunity and uncertainty. In this dynamic landscape, Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) stan...

Forging New Frontiers in Cancer Treatment: Perspective Therapeutics Amplifies Hope with 212PbVMTNET Trial Progress In the ever-evolving realm of cancer treatment, innovation is paramount. This week, at the esteemed 2024...

Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a leading innovator in the field of radiopharmaceuticals, has announced exciting developments in their pioneering cancer treatment efforts. This news comes ahead of...

Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a forward-thinking company in the field of radiopharmaceuticals, has reached a significant milestone with the commencement of shipments and patient dosing from its n...

Author: Affiliation: Your Institution Published in: CSIMarket.com Date: October 11, 2024 : The emergence of radiopharmaceutical therapies has invigorated the scientific community s efforts to address treatment-resistant...

In an era where cancer treatment continues to evolve, Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a leading radiopharmaceutical company, is set to present groundbreaking research at several prestigious interna...

Perspective Therapeutics to Illuminate Advances in Radiopharma at Key Oncology Summits In a significant move poised to enhance its visibility and influence within the rapidly evolving field of oncology, Perspective Ther...

Perspective Therapeutics to Present Pioneering Data and Expound on FDA Fast Track Designation at EANM Annual Congress SEATTLE, Sept. 30, 2024 - Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), an innovative leader...

In a striking showcase that captivated attendees at the World Molecular Imaging Congress (WMIC) 2024, held from September 9-13 in Quebec, Canada, Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) unveiled groundbreak...

Perspective Therapeutics Joins the Russell 3000 Index and Showcases Innovation at SNMMI Annual Meeting Amid Successful $80 Million Offering SEATTLE, June 12, 2024 Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a...

In a significant move aimed at optimizing shareholder value, Perspective Therapeutics, Inc. (CATX), a pioneering radiopharmaceutical company specializing in advanced cancer treatment applications, recently announced its...

Perspective Therapeutics Makes Waves at Radiopharmaceutical ConferencePerspective Therapeutics, a leading radiopharmaceutical company, showcased its cutting-edge alpha-particle radiopharmaceuticals at the SNMMI 2024 Ann...

Perspective Therapeutics Announces $80 Million Underwritten Offering Amidst Expanding Innovations in Cancer Treatment Seattle, May 24, 2024 Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a leading radiopharmaceut...